Anatumomab mafenatox

N/A

Report date: 2023/02/12 00:16:03

Base Information

Drug NameAnatumomab mafenatox
Drug Alias Name麻安莫单抗TTS CD2PNU-214936ABR-214936TTS CD2 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionImmunostimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsTrophoblast glycoprotein
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesActive Biotech Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesActive Biotech Ab
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksWikipedia